Dragonfly Therapeutics develops novel first-in-class therapeutics targeted at Natural Killer cells and other cells of the innate immune system. Dragonfly's therapies are designed to counterbalance immune suppressive factors present in the tumor microenvironment and mobilize anti-cancer immune responses, and are expected to be potent as single agents as well as in treatment combinations with existing cancer immunotherapies – such as T cell treatments.
